Stryker Invests About $400 Million in CMR Surgical and Takes an Option on the Rest

Stryker announced on October 12 that it will make a preferred equity investment of about $400 million, or £300 million, in CMR Surgical, the Cambridge, UK maker of the Versius surgical robot. The company also gets an exclusive option to buy all of CMR's outstanding equity, according to Stryker's release.

The investment is subject to customary closing conditions, and the release gives no closing date. The option is separate: any purchase would need regulatory approvals and has no announced price. This is an announced investment with an option attached, not an acquisition.

What Stryker bought, and what it did not

Stryker becomes the exclusive U.S. sales agent for the Versius portfolio. CMR keeps development and commercialization everywhere outside the U.S. Andy Pierce, Group President, Medsurg and Neurotechnology at Stryker, called soft-tissue robotics "a high-growth adjacency." CMR's chief executive, Massimiliano Colella, called the alliance "a significant milestone for CMR," and Pierce will join CMR's board.

MedTech Dive does not give Stryker's ownership stake, CMR's valuation or CMR's earlier funding, and Stryker's release does not either. One outlet has put the stake near 10 percent at a $4 billion valuation, but that figure was not in either primary document, so it is not used here. Without a stake or a price for the option, an implied multiple against CMR's revenue cannot be calculated, and CMR does not publish revenue in these sources.

Where Versius stands in the U.S.

CMR was founded in 2014. Its current product is Versius Plus, a modular system that can be moved between operating rooms. MedTech Dive reports the FDA has cleared CMR's latest system for gallbladder procedures, and that CMR plans to seek more soft-tissue indications.

J.P. Morgan analyst Robbie Marcus said CMR had performed more than 45,000 procedures globally as of early 2026. Stifel analyst Rick Wise put CMR at roughly second or third in global installed base. Wise called it "a now or never moment for Stryker to make the decision."

Marcus was blunter about the near term. He said "we don't think Stryker/CMR will be effective at displacing da Vinci" in the U.S., and that the deal is likelier to hurt Medtronic and Johnson & Johnson at the margins. He expects Stryker to start in lower-cost facilities such as ambulatory surgery centres.

Company	System	U.S. position, per MedTech Dive
Intuitive	da Vinci	Market leader
Johnson & Johnson	Ottava	FDA authorized
Medtronic	Hugo	FDA authorized
CMR Surgical	Versius Plus	Cleared for gallbladder procedures; Stryker to sell

Why a medical-device group bought a minority position

Stryker already runs a robot business. Its Mako orthopedic system reported record installations in the first quarter, MedTech Dive said. Soft tissue is a different market, and Stryker is entering it through a minority investment and a U.S. sales agreement rather than building a platform.

The structure matters for CMR's other investors. Preferred equity ranks ahead of common shares in a sale, and the option lets Stryker choose its moment. The terms of both are undisclosed. For other money moving into surgical and physical-A.I. hardware this month, see our report on Mind Robotics and its $1 billion with no product.

See also the third-quarter cybersecurity funding tally for how deal counts and sizes are diverging. The next observable event is the closing of the investment. Stryker has not said when that is expected.